首页> 外国专利> NANOTHERAPY TARGETING RHAMM-POSITIVE TUMORS

NANOTHERAPY TARGETING RHAMM-POSITIVE TUMORS

机译:纳米疗法靶向RHAMM阳性肿瘤

摘要

The present technology is directed to nanoparticle compositions and methods useful in treating RHAMM-positive cancers. Such nanoparticle compositions include a plurality of nanoparticles where each nanoparticle includes (i) a particle core with an outer surface; a first layer coating the outer surface of the particle core, the first layer including one or both of poly-L-lysine and poly-L-arginine and optionally including a fluorescent dye; a second layer coating the first layer, the second layer including one or more siRNA that inhibit expression of Bcl-2, inhibit expression of Bcl-xL (BCL2L1), inhibit expression of MCL1, inhibit expression of Bcl-w (BCL2L2), inhibit expression of Bcl-b (BCL2L10), and/or inhibit expression of BFL1 (BCL2A1); a third layer coating the second layer, the third layer including an apoptotic peptide and optionally including a fluorescent dye; and a fourth layer coating the third layer, the fourth layer including hyaluronic acid or a pharmaceutically acceptable salt thereof (HA); and where the plurality of nanoparticles has an intensity- weighted average diameter as determined by dynamic light scattering from about 100 nm to about 300 nm; or (ii) a particle core with an outer surface; a first layer coating the outer surface of the particle core, the first layer including an apoptotic peptide and optionally including a fluorescent dye; a second layer coating the first layer, the second layer including one or more siRNA that inhibit expression of Bcl-2, inhibit expression of Bcl-xL (BCL2L1), inhibit expression of MCL1, inhibit expression of Bcl-w (BCL2L2), inhibit expression of Bcl-b (BCL2L10), and/or inhibit expression of BFL1 (BCL2A1); a third layer coating the second layer, the third layer including one or both of poly-L-lysine and poly-L-arginine and optionally including a fluorescent dye; and a fourth layer coating the third layer, the fourth layer including hyaluronic acid or a pharmaceutically acceptable salt thereof (HA); and where the plurality of nanoparticles has an intensity-weighted average diameter as determined by dynamic light scattering from about 100 nm to about 300 nm.
机译:本技术涉及可用于治疗RORAMP阳性癌症的纳米颗粒组合物和方法。这种纳米颗粒组合物包括多个纳米颗粒,其中每个纳米颗粒包括(i)具有外表面的颗粒芯;涂覆颗粒芯的外表面的第一层,第一层包括聚-L-赖氨酸和聚 - 精氨酸中的一种或两种,任选地包括荧光染料;涂覆第一层的第二层,第二层包括抑制Bcl-2表达的一个或多个siRNA,抑制Bcl-xl(bcl2l1)的表达,抑制Mcl1的表达,抑制Bcl-w(bcl2l2)的表达,抑制Bcl-b(bcl2l10)的表达,和/或抑制bfl1(bcl2a1)的表达;涂覆第二层的第三层,第三层包括凋亡肽,任选地包括荧光染料;和涂覆第三层的第四层,第四层包括透明质酸或其药学上可接受的盐(HA);在多个纳米颗粒具有强度加权的平均直径,如通过约100nm至约300nm的动态光散射所确定的;或(ii)具有外表面的颗粒芯;涂覆颗粒芯的外表面的第一层,第一层包括凋亡肽,任选地包括荧光染料;涂覆第一层的第二层,第二层包括抑制Bcl-2表达的一个或多个siRNA,抑制Bcl-xl(bcl2l1)的表达,抑制Mcl1的表达,抑制Bcl-w(bcl2l2)的表达,抑制Bcl-b(bcl2l10)的表达,和/或抑制bfl1(bcl2a1)的表达;涂覆第二层的第三层,第三层包括聚-L-赖氨酸和聚-L-精氨酸中的一种或两种,任选地包括荧光染料;和涂覆第三层的第四层,第四层包括透明质酸或其药学上可接受的盐(HA);在多个纳米颗粒具有强度加权平均直径的情况下,通过动态光散射从约100nm至约300nm确定。

著录项

  • 公开/公告号WO2021216997A3

    专利类型

  • 公开/公告日2021-12-02

    原文格式PDF

  • 申请/专利权人 CORNELL UNIVERSITY;

    申请/专利号WO2021US28834

  • 申请日2021-04-23

  • 分类号A61P35/04;C07K14/705;G01N33/50;C12N15/113;A61K31/726;A61K38/17;A61K47/36;A61K48;

  • 国家 US

  • 入库时间 2024-06-14 22:28:34

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号